Investigational Treatment for Acute Myeloid Leukemia

Trial ID:
IRB-16-6832
Marin Xavier, MD
This study will evaluate the efficacy of the investigational drug, inecalcitol, in combination with decitabine. Research shows that inecalcitol impacts how cancer cells multiply, so adding the drug to decitabine could improve the response and duration of remission compared with decitabine alone.

Inclusion Criteria

  • Be between 65 and 75 years old

Exclusion Criteria

  • Have had prior treatment with decitabine, azacitidine, or cytarabine

Contact Info:

  • Shannon Cyhan
  • cyhan.shannon@scrippshealth.org
  • 619-849-4469